Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.49 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | STK25 | O00506 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13315133 | 0.76 | ALDH1A1 (0.43) | STK25ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13315134 | 0.75 | MEN1 (0.42) | MAPK14STK25ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13487581 | 0.73 | RAB9A (0.40) | MAPK14STK25ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13487582 | 0.72 | ALDH1A1 (0.53) | MAPK14RAF1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL13487547 | 0.72 | MAPK14 (0.56) | MAPK14RAF1 | |
| SCHEMBL13315141 | 0.71 | MAPT (0.43) | ALDH1A1SMN1; SMN2KMT2AMEN1HTT | |
| SCHEMBL3545638 | 0.69 | MAPK14 (0.67) | MAPK14 | |
| SCHEMBL13487574 | 0.67 | MAPK14 (0.56) | MAPK14 | |
| SCHEMBL3241540 | 0.66 | MAPK14 (1.00) | MAPK14RAF1 | |
| SCHEMBL3242741 | 0.64 | MAPK14 (1.00) | MAPK14RAF1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | MAPK14 33/4885RAF1 74/4885STK25 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.